Balyasny Asset Management
IMMX icon

Balyasny Asset Management’s Immix Biopharma IMMX Stock Holding History

Balyasny Asset Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,854
Closed -$67.2K – 3186
2025
Q4 		$67.2K Buy
+12,854
New +$52.9K ﹤0.01% 2992

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Balyasny Asset Management's IMMX Position: Q1 2026 in Review

Balyasny Asset Management sold out of Immix Biopharma (IMMX) in Q1 2026, closing a stake of 12,854 shares — an estimated $67.2K sold.

Balyasny Asset Management first reported a position in IMMX in Q4 2025 and held it in 1 quarter. The position peaked at $67.2K in Q4 2025. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Balyasny Asset Management reported no remaining Immix Biopharma position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 12,854 Immix Biopharma shares in Q1 2026, an estimated $67.2K.
  • Balyasny Asset Management first reported a position in Immix Biopharma in Q4 2025 and held it in 1 quarter.
  • Balyasny Asset Management's Immix Biopharma position peaked at $67.2K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.